251 related articles for article (PubMed ID: 24644116)
21. Effectiveness, safety, and costs of thromboprophylaxis with enoxaparin or unfractionated heparin in inpatients with obesity.
Amin A; Kartashov A; Ngai W; Steele K; Rosenthal N
Front Cardiovasc Med; 2023; 10():1163684. PubMed ID: 37396589
[TBL] [Abstract][Full Text] [Related]
22. Venous thromboembolism clinically detected after hip fracture surgery with prophylaxis in a clinical practice setting.
Comp P; Happe LE; Sarnes M; Farrelly E
Am J Orthop (Belle Mead NJ); 2008 Sep; 37(9):470-5. PubMed ID: 18982184
[TBL] [Abstract][Full Text] [Related]
23. Cost consequence analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery in Belgium.
Annemans L; Minjoulat-Rey MC; De Knock M; Vranckx K; Czarka M; Gabriel S; Haentjens P
Acta Clin Belg; 2004; 59(6):346-57. PubMed ID: 15819379
[TBL] [Abstract][Full Text] [Related]
24. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal.
Holmes M; Carroll C; Papaioannou D
Health Technol Assess; 2009 Sep; 13 Suppl 2():55-62. PubMed ID: 19804690
[TBL] [Abstract][Full Text] [Related]
25. Short-term therapy with enoxaparin or unfractionated heparin for venous thromboembolism in hospitalized patients: utilization study and cost-minimization analysis.
Argenta C; Ferreira MA; Sander GB; Moreira LB
Value Health; 2011; 14(5 Suppl 1):S89-92. PubMed ID: 21839908
[TBL] [Abstract][Full Text] [Related]
26. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
[TBL] [Abstract][Full Text] [Related]
27. Comparison of Venous Thromboembolism Prophylactic Measures Post Coronary Artery Bypass Graft Surgery.
Wilsey HA; Pandya K; Beavers C; Xiaoshu L; Ather A
Am J Cardiovasc Drugs; 2019 Dec; 19(6):589-595. PubMed ID: 31203501
[TBL] [Abstract][Full Text] [Related]
28. A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention.
Revankar N; Patterson J; Kadambi A; Raymond V; El-Hadi W
Postgrad Med; 2013 Jul; 125(4):141-53. PubMed ID: 23933902
[TBL] [Abstract][Full Text] [Related]
29. Identifying orthopedic patients at high risk for venous thromboembolism despite thromboprophylaxis.
Schiff RL; Kahn SR; Shrier I; Strulovitch C; Hammouda W; Cohen E; Zukor D
Chest; 2005 Nov; 128(5):3364-71. PubMed ID: 16304285
[TBL] [Abstract][Full Text] [Related]
30. Association of Anti-Factor Xa-Guided Dosing of Enoxaparin With Venous Thromboembolism After Trauma.
Karcutskie CA; Dharmaraja A; Patel J; Eidelson SA; Padiadpu AB; Martin AG; Lama G; Lineen EB; Namias N; Schulman CI; Proctor KG
JAMA Surg; 2018 Feb; 153(2):144-149. PubMed ID: 29071333
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing hip fracture surgery.
Sullivan SD; Kwong L; Nutescu E
Value Health; 2006; 9(2):68-76. PubMed ID: 16626410
[TBL] [Abstract][Full Text] [Related]
32. Retrospective Evaluation of Venous Thromboembolism Prophylaxis in Elderly, High-Risk Trauma Patients.
Krantz EN; Philpott CD; Droege ME; Mueller EW; Ernst NE; Garber PM; Tsuei BJ; Goodman MD; Droege CA
J Surg Res; 2020 May; 249():225-231. PubMed ID: 31991331
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in major orthopedic surgery: findings from the ORTHO-TEP registry.
Beyer-Westendorf J; Lützner J; Donath L; Radke OC; Kuhlisch E; Hartmann A; Weiss N; Werth S
J Thromb Haemost; 2012 Oct; 10(10):2045-52. PubMed ID: 22882706
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.
Mehta SR; Granger CB; Eikelboom JW; Bassand JP; Wallentin L; Faxon DP; Peters RJ; Budaj A; Afzal R; Chrolavicius S; Fox KA; Yusuf S
J Am Coll Cardiol; 2007 Oct; 50(18):1742-51. PubMed ID: 17964037
[TBL] [Abstract][Full Text] [Related]
35. New versus established drugs in venous thromboprophylaxis: efficacy and safety considerations related to timing of administration.
Tribout B; Colin-Mercier F
Am J Cardiovasc Drugs; 2007; 7(1):1-15. PubMed ID: 17355162
[TBL] [Abstract][Full Text] [Related]
36. Safety and Efficacy of High-Dose Unfractionated Heparin Versus High-Dose Enoxaparin for Venous Thromboembolism Prevention in Morbidly Obese Hospitalized Patients.
Mason SW; Barber A; Jones E; Chen SL; Moll S; Northam K
Am J Med; 2020 Jun; 133(6):e249-e259. PubMed ID: 31862336
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness, Safety, and Costs of Thromboprophylaxis with Enoxaparin or Unfractionated Heparin Among Medical Inpatients With Chronic Obstructive Pulmonary Disease or Heart Failure.
Amin AN; Kartashov A; Ngai W; Steele K; Rosenthal N
J Health Econ Outcomes Res; 2024; 11(1):44-56. PubMed ID: 38390025
[No Abstract] [Full Text] [Related]
38. Recurrence of Venous Thromboembolism in Patients With Cancer Treated With Warfarin.
Marshall AL; Campigotto F; Neuberg D; Rowe B; Connors JM
Clin Appl Thromb Hemost; 2015 Oct; 21(7):632-8. PubMed ID: 25850917
[TBL] [Abstract][Full Text] [Related]
39. Systematic review of randomized controlled trials of new anticoagulants for venous thromboembolism prophylaxis in major orthopedic surgeries, compared with enoxaparin.
Yoshida Rde A; Yoshida WB; Maffei FH; El Dib R; Nunes R; Rollo HA
Ann Vasc Surg; 2013 Apr; 27(3):355-69. PubMed ID: 23351997
[TBL] [Abstract][Full Text] [Related]
40. Effects of fondaparinux compared with dalteparin, enoxaparin and unfractionated heparin on human osteoblasts.
Matziolis G; Perka C; Disch A; Zippel H
Calcif Tissue Int; 2003 Oct; 73(4):370-9. PubMed ID: 12874702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
